Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis
- 1 July 2020
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4), e13497
- https://doi.org/10.1111/dth.13497
Abstract
Many patients with psoriasis fail to respond to biologic drugs either initially or lose response over time, the latter having predominantly been linked to low circulating drug levels. We examined how serum drug levels varied over three treatment cycles of stable maintenance therapy with either adalimumab or infliximab among a total of 28 patients with psoriasis (22 men, mean age 48.6 years, mean treatment time 6.2 years) and whether there was an association with various patient-specific factors. The range for all concentrations was 1.1 to 24.3 mu g/mL for adalimumab and 0.0 to 180.6 mu g/mL for infliximab. There was a consistent inverse association between body mass index (BMI) and trough and maximum serum concentrations of adalimumab (P < .05 for all comparisons) and a positive, less consistent, association between age and maximum serum concentration of infliximab (P < .05 for both comparisons). Patient-specific factors, such as BMI and age, can help predict fluctuations in serum concentrations of biologics used for psoriasis.This publication has 9 references indexed in Scilit:
- Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic ModelJournal of Pharmacy & Pharmaceutical Sciences, 2018
- Fixed Dosing of Monoclonal Antibodies in OncologyThe Oncologist, 2017
- Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomesNature Reviews Gastroenterology & Hepatology, 2016
- Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of PsoriasisJAMA Dermatology, 2015
- Lack of Anti-drug Antibodies in Patients with Psoriasis Well-controlled on Long-term Treatment with Tumour Necrosis Factor InhibitorsActa Dermato-Venereologica, 2012
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendationsJournal of the American Academy of Dermatology, 2010
- Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendationsCurrent Medical Research and Opinion, 2010
- An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody statusClinical Rheumatology, 2008
- An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of InfliximabTherapeutic Drug Monitoring, 2006